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Introduction Mechanism-based inactivation (MBI) of cytochrome P450 (CYP) enzymes represents several challenges for the development of therapeutics. Foremost, MBI has the potential to amplify the magnitude of a drug-drug interaction (DDI), by changing the clearance of coadministered drugs and ultimately, affecting patient safety (Fletcher et al., 2000; Miller et al., 2007; Fernandez-Montero et al., 2009) . The MBI-mediated rate of inactivation relative to zeroorder synthesis rate of new enzyme provides a path for estimating the magnitude of inhibition a MBI will have on drug disposition (Mayhew, 2000) . However reactive metabolites, often the precursors to MBI, are less understood (Begriche et al., 2011) and predicting the impact of the reactive metabolites on safety is difficult. Therefore, it remains critical to understand the mechanism of bioactivation of CYP inhibitors to characterize the chemical entities that predispose MBI, which is challenging in part due to the diversity of CYP oxidative chemistry.
Ritonavir ( Figure 1 ) is a rationally designed protease inhibitor for the treatment of human immunodeficiency virus (HIV) and a well-known inactivator of CYP3A (Koudriakova et al., 1998) .
Inactivation of intestinal and hepatic CYP3A during initial transit of the oral dose of ritonavir increases the bioavailability and decreases the rate of systemic elimination. These effects, in part, explain the high bioavailability and longer half-life of ritonavir, compared with other protease inhibitors (Koudriakova et al., 1998) . Consequently, a standard HIV therapy combination makes use of an intentional DDI, where ritonavir is used to boost concentrations of other co-administered protease inhibitors by decreasing clearance via CYP3A inactivation. The dose of ritonavir administered in "boosted" protease inhibitor regimens is generally considered sub-therapeutic (100-200 mg) (Moyle and Back, 2001) . The discovery that a low dose of ritonavir can be safely administered to enhance the effectiveness of other protease inhibitors has drastically reduced the adverse effects and improved the efficacy of treatment (Hirsch et al., MOL# 94862 5 2008). However, this pharmaco-enhancement effect does come with a cost because the safety and efficacy of numerous other medications metabolized by CYP3A is compromised.
The potent inhibitory effect on CYP3A4 by ritonavir has been demonstrated in in vitro preparations including expressed CYP3A4 enzyme, human enterocytes and human liver microsomes (HLMs) (Koudriakova et al., 1998 (Blobaum et al., 2002; Ortiz de Montellano, 2005) .
The structural complexity of ritonavir precludes the ready identification of the chemical moiety that undergoes bioactivation to an intermediate that would inactivate CYP3A. It has been proposed that ritonavir forms an MI complex with CYP3A4 (Ernest et al., 2005) ; however, the reactive metabolite(s) responsible for the formation of an MI complex or a proposed structure of the MI complex have not been reported. Additionally, it was demonstrated in one study that other protease inhibitors including amprenavir, nelfinavir and indinavir, are capable of forming MI complexes with CYP3A4 based on spectral evidence in CYP3A4 expressed enzymes (Ernest et al., 2005) , however the authors were not able to generate MI complexes with ritonavir in HLMs, where CYP3A4 is the dominant CYP enzyme. Ritonavir is also reported to be a tight, irreversible binding inhibitor of CYP3A4 via coordination to the heme iron (Sevrioukova and MOL# 94862 6 thiazolylmethyl group to form a primary amine. A possible route for MI complex formation is via further metabolism of this primary amine, based on numerous reports of the ability of substituted aliphatic amines to form MI complexes with CYP enzymes under turnover conditions (Bensoussan et al., 1995; Ortiz de Montellano, 2005) .
The postulated formation of an MI complex may not be the only viable mechanism for inactivation of CYP3A4 by ritonavir, especially considering formation of the MI complex only accounts for 64% of the inactivated CYP3A4 (Ernest et al., 2005) . Inhibition studies using M1 or any metabolite of ritonavir have not been reported, although there is data demonstrating that metabolites of ritonavir (generated in situ) added to a secondary incubation had no effect on the rate of metabolism of ritonavir by intact microsomes (Koudriakova et al., 1998) . Additionally, comparison of the ability of ritonavir and structural analogs to inactivate the enzyme showed that the potent inhibitory properties of ritonavir require the presence of both the 2'-isopropylthiazolyl and 2-(1-methylethyl)thiazolyl groups (Kempf et al., 1997) . The aim of this work is to further characterize the mechanism(s) of CYP3A4 inactivation by ritonavir by evaluating, MI complex formation, heme-adduct formation, and irreversible covalent binding to CYP3A4.
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Materials and Methods

Materials
All commercial solvents (Sigma-Aldrich) were of analytical grade with the exception of solvents used with the Waters Acquity Ultra Performance Liquid Chromatography (UPLC), which were LC/MS Optima ® grade. CYP 3A4 Supersomes™ were purchased from BD Biosciences (Franklin Lakes, NJ). CYP 3A4 was co-expressed with cytochrome b 5 and cytochrome CYP reductase.
Human CYP 3A4 was expressed and purified as described previously (Baer et al., 2007 Bank (Seattle, WA). All other chemicals were purchased from Sigma-Aldrich, unless specified.
CYP 3A4 activity assay
The turnover of midazolam to 1'-OH midazolam was used to probe the activity of CYP 3A4. The peaks eluted using a linear gradient at 0.3 mL/minutes and mobile phases A: 0.1% formic acid in water and B: 0.1% formic acid in acetonitrile. The gradient started at 90% A (0-0.5 minutes). Solvent B was linearly increased from 10% at 0.5 minutes to 100% at 3 minutes. The total run time was 4 minutes. The cone and collision energies were 25 V and 15 kV respectively, for both channels. (IC 50 = 0.05 uM, (Ernest et al., 2005) ); therefore, 1:100 dilutions were made into the activity assay to minimize the effect of competitive inhibition of midazolam hydroxylation in the activity assay. After three min, the activity assay was quenched with an equal volume ACN containing 0.5 µM of internal standard performed in triplicate. The same experimental setup described above was used to measure CYP3A4 inactivation in reconstituted 3A4 (incubation conditions described below in CO difference spectral analysis) to establish the inactivation profile was the same in each system.
CYP 3A4 inactivation assay
CYP3A4
Additionally, the rate of inactivation of CYP 3A4 Supersomes™ by ritonavir (1.5 µM) was determined in the presence of the following nucleophilic trapping agents: L-glutathione (1 mM), N-acetyl cysteine (1 mM), N-acetyl lysine (1 mM) and potassium cyanide (0.5 mM).
Rates of enzyme inactivation (k obs ) were estimated from the slopes of the semi-log plots of percent remaining enzyme activity in the presence and absence of inactivator with time. Kinetic parameters for enzyme inactivation were obtained by nonlinear regression without weighting using Sigma Plot 9.0 (Systat Software, Inc., San Jose, CA) where k obs is related to the inhibitor concentration (I) according to the following equation:
where k inact is the maximal inactivation rate constant and K I is the inhibitor concentration that produces a k obs that is half k inact . This equation assumes that the loss of enzyme is due solely to inactivation by the inhibitor, and that there is negligible change in the inhibitor concentration throughout the incubation; therefore, preliminary experiments were performed to determine appropriate concentrations of enzyme and inhibitor to use in order to avoid depletion.
Metabolic-intermediate complex formation
CYP 3A4 Supersomes™ or HLMs were used to characterize MI complex formation associated with the metabolism of ritonavir, N-ritonavir and a positive control, troleandomyocin. (Liu and Franklin, 1985) . from the higher ratios of inhibitor to CYP 3A4 as previously described (Silverman, 1988) .
CO difference spectral analysis
Purified CYP 3A4 was reconstituted with 60 µg of a (1:
-phosphcholine, and L-α-phosphatidylserine, 200 µg of sodium cholate, 100 U catalase, 2mM glutathione in a 1 molar ratio of CYP 3A4 to CYP reductase and 0.5 molar ratio of CYP 3A4 to cytochrome b 5 . This mixture was transfered into buffer containing 50 mM HEPES (pH 7.4), 20% glycerol, 30 mM MgCl 2 , and 0.5 mM EDTA to a total volume of 1 mL, as previously described (Shaw et al., 1997) . Ritonavir or 1-aminobenzotriazole (10 µM) was incubated with the reconstituted CYP 3A4 mixture (0.05 µM) in the presence and absence of NADPH at 37ºC for 30 minutes. The reaction mixture was split into a reference and sample cuvette to determine CYP content by CO difference spectra. The reduced CO difference spectrum was determined by first reducing the enzyme, in both the reference and sample cuvettes, with sodium dithionite and obtaining a baseline spectrum by MOL# 94862
scanning from 400-500 nm on an Aminco DW-2 spectrophotometer (Olis, Bogart, GA). The sample cuvette was then bubbled with CO for approximately 1 minute, and the spectrum was acquired. At the end of 30 minutes an aliquot was removed and CYP3A4 activity was measured.
Trapping of reactive intermediates with nucleophilic reagents
The following nucleophilic trapping agents, L-glutathione (1 mM grade trypsin or proteinase K (Roche, Indianapolis, IN) in a 1:50 (w/w) ratio for 12 hours at room temperature. The pH was adjusted to 5 with 0.1% TFA and 100 µL of ACN was added to final of 1 mL. Samples were desalted using a standard solid phase extraction protocol (SPE) with a Vydac silica C 18 macrospin column (The Nest Group, Southborough, MA). Eluate was concentrated by SpeedVac to a volume of 20 µL and frozen at -80ºC until mass spectral analysis.
Mass Spectral Analysis of CYP 3A4 Peptides
The peptides resulting from digests, described above, of CYP 3A4 and The modified peptides were also identified based on LC-radiometric trace.
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Results
Time-dependent inactivation of CYP 3A4 by ritonavir and metabolite, N-ritonavir
Ritonavir and a primary metabolite, N-ritonavir ( Figure 1 ) were determined to be a potent, time-dependent inactivator of CYP 3A4 with a K I = 0.59 and 1.4 µM and k inact = 0.53 and 0.33 min -1 , respectively (Table 1) . A substrate depletion-based partition ratio was determined for both inhibitors. The percentage of CYP 3A4 activity remaining at 10 minutes was plotted as a function of the molar ratio of inhibitor to CYP 3A4. The turnover number was estimated from the intercept of the lower linear ratios of inhibitor to CYP 3A4 with the line derived from the higher ratios of inhibitor to CYP 3A4 (data not shown). By this method, the turnover number minus one is equal to the substrate-based depletion partition ratio (Silverman, 1988) . Partition ratio estimates for ritonavir and N-ritonavir was 19 ± 3 and 12 ± 2, respectively ( Table 1 ). The inactivation rate of ritonavir was also determined in the presence of four nucleophilic trapping agents (0.5 mM KCN, 1 mM N-acetyl cysteine, 1 mM N-acetyl lysine and 1 mM L-glutathione).
In each case, the rate of inactivation was not altered by inclusion of the trapping reagents (Supplemental Figure 4) . Additionally, co-incubations with the nucleophilic trapping agents (e.g.
KCN, GSH) and [
3 H]-ritonavir did not indicate the formation of any adducts to ritonavir both from LC/MS analysis and LC-radiometric traces.
CYP 3A4 MI complex formation
Spectrophotometric absorbance difference spectra of CYP 3A4 Supersomes™ and complex, leading to a loss of the peak at 455 nm and a restoration of catalytic activity (Schenkman et al., 1972) . Thus, experiments with subsequent K 3 [Fe(CN) 6 ] addition followed by activity measurements were performed with CYP 3A4 in the presence of ritonavir as well as Nritonavir and troleandomycin (Delaforge et al., 1984) (Figure 2 ). As expected, the addition of 1 mM K 3 [Fe(CN) 6 ] regenerated the activity of CYP 3A4 in the N-ritonavir and troleandomycin incubations. However, the activity of CYP 3A4 was not restored in the case of ritonavir. Under co-incubation condition with equal molar amounts of ritonavir and N-ritonavir, no formation of an MI complex was observed (Figure 2 ). Together, these findings demonstrate that an inactivating MI complex is not formed by CYP 3A4 metabolism of ritonavir.
CYP 3A4 CO binding
The observation that metabolism of ritonavir does not lead to the formation an MI complex with CYP 3A4, but does lead to enzyme inactivation, led to the consideration that ritonavir is metabolized to a reactive intermediate that is capable of forming a covalent bond to prosthetic heme of CYP 3A4. A CO-binding experiment was performed to explore this possibility, given that alkylated prosthetic heme will not form a characteristic CYP CO-difference spectrum. The spectral experiments with reconstituted CYP 3A4 revealed no significant difference in the 450 nm absorbance between the control sample (-NADPH) and the sample treated with ritonavir and NADPH (Figure 3 ). This result, in addition to no radioactivity bound to the heme iron (Figure 4 ), demonstrate that a heme adduct is not formed during enzyme inactivation by ritonavir. Figure 5 ). The stoichiometry was also determined based on CYP 3A content. In agreement with the CO-binding study, there was no radioactivity associated with the heme peak of CYP 3A4. Figure 6 ).
Covalent binding to CYP 3A4 by ritonavir
A fraction of the incubation used for whole protein mass spectral analysis was subjected to tryptic and proteinase K digestion to identify the specific amino acid adducted by bioactivated ritonavir. Incubations with [ 3 H]-ritonavir were also subjected to tryptic and proteinase K digestion which enabled quantitation of [ 3 H]-ritonavir bound to peptides via LC-radiochromatography. The radiochromatograph of the tryptic digests revealed a single peak at 21.5 minutes (Supplemental Figure 1) . The counts associated with this peak were calculated to be 87% of the total CYP 3A content, in alignment with the precipitated protein binding studies ( Figure 5 ). Conversely, radiochromatograph of the proteinase K digests did not reveal any radioactive peaks. LC/MSMS data for both digests were acquired using an LTQ-OT, and data was searched using SEQUEST From the tryptic digest dataset, CYP 3A4 was identified with 74 % sequence coverage. The analyses revealed that Lys257 was the adducted amino acid in the modified peptide sequence of 255-RMKESRLEDTQKHR-268. The observed doubly charged precurosor ion was within 12.3 ppm of the theoretical values, and all annotated fragment ions were within 8 ppm ( Figure   7 ). The identity of the modified peptide was further characterized by manual inspection of the MS/MS spectra. For example, an ion (m/z 749.12) corresponded to the loss of ritonavir plus the nitrogen from the adducted lysine residue on the peptide (Figure 7) , further confirming the site of modification. In the controls, minus NADPH or minus ritonavir, the adducted peptide was not observed.
This article has not been copyedited and formatted. The final version may differ from this version. From the data of the proteinase K digest CYP 3A4 was identified with 89% sequence coverage. Based on the lack of a radioactive peptide peak in the proteinase K digests, the stability of ritonavir under proteinase K digestion conditions was evaluated. Ritonavir is cleaved into two fragments under the digestion conditions (Supplemental Figure 2) . The lack of stability of ritonavir under the digestion conditions also explains the loss of radioactivity from the adducted peptide. Knowledge of this unique cleavage allowed different modifications of CYP 3A4 by ritonavir to be searched for in the data. This revealed a similar adducted peptide (255-RMK*E-258, observed within 13.4 ppm of the theoretical value) to the same amino acid (Lys257) as was observed in the tryptic digest (Supplemental Figure 3) . The MS/MS data also confirmed the adduct localization on the isopropyl-end of ritonavir, with all assigned fragment ions within 5 ppm of the theoretical values. In the control data, (minus NADPH or minus ritonavir) the adducted peptide was not observed.
Discussion
The potent inhibitory effect on CYP3A4 by ritonavir has been demonstrated across in vitro preparations including expressed CYP3A4 enzyme (Supersomes™), purified, reconstituted 3A enzyme, human enterocytes and human liver microsomes (Kumar et al., 1996; Koudriakova et al., 1998; Ernest et al., 2005) . Additionally, the therapeutic use of ritonavir as a "booster" for other HIV protease inhibitors demonstrates that ritonavir is also an effective in vivo CYP3A4
inhibitor (Kempf et al., 1997) . However, the mechanism(s) that are responsible for the inactivation of CYP3A4 by ritonavir remain unknown. The structural complexity of ritonavir precludes the identification a potential chemical moiety for bioactivation. Given the diversity of CYP-mediated bioactivation reactions, it is common for competing mechanisms of inhibition to occur. For example, 17-α-ethynylestradiol inactivates CYP3A by both heme modification and covalent binding to the protein (Lin and Hollenberg, 2007) . The three possible routes of CYP3A4 inactivation (MI complex formation, heme modification and apoprotein adduction) were investigated to elucidate the mechanism of ritonavir mediated CYP3A4 inactivation.
A previous report proposed that ritonavir inactivated CYP3A4 via the formation of an MI complex with rapid loss of enzyme activity (Ernest et al., 2005 ) (K I = 0.59 µM; k inact = 0.53 min -1 ).
Therefore, the precursor to inactivation must arise from multiple oxidative reactions with ritonavir and is likely a result of sequential metabolism. Converse to these results, in this study no MI complex was observed with ritonavir and CYP3A4; whereas, under similar conditions an MI complex was observed with the positive control troleandomycin. In addition, ferricyanide reversed the MI complex with troleandomycin, however activity was not restored with ritonavir.
The discrepancy in the ability to observe MI complex formation could be related to experimental design including ritonavir concentration, analytical techniques or complexities of sequential metabolism kinetics.
This article has not been copyedited and formatted. The final version may differ from this version. heme chromophore after incubations with ritonavir suggest that inactivation occurs through a mechanism independent of heme destruction. This is contrary to the recent report by Lin et. al (Lin et al., 2013) where the authors found that ritonavir inactivation of CYP3A4 was due to heme destruction with the formation of a heme-protein adduct, and no significant modification of the apoprotein. The report of heme destruction and a heme-protein adduct were performed with reconstituted CYP3A4 and CYP reductase, in comparison to the studies performed here in both CYP 3A4 Supersomes™ and reconstituted 3A4 enzyme with reductase and cytochrome b 5 .
More so, Lin et al. report the formation of glutathione adducts which were not observed in our studies. The difference in ritonavir metabolism and the role that cytochrome b 5 may play in the activation of ritonavir (and possibly other CYP3A4 substrates) is worthy of further research.
However, the results reported here, led to the hypothesis that the metabolism of ritonavir inhibits CYP3A4 by the formation of a covalent adduct to the apoprotein of CYP3A4.
Covalent labeling of CYP apoprotein has been shown to be the cause of inactivation for a structurally diverse set of compounds including terminal acetylenes such as 1-ethynylpyrene (Gan et al., 1984) , furan-containing compounds such as furafylline (Racha et al., 1998) , 8-methoxypsoralen (Labbe et al., 1989) and bergamottin (He et al., 1998) and halogenated compounds such as chloramphenicol (Halpert, 1982) . The identification of CYP3A4 apo adducts and the chemical entities responsible for inactivating CYP3A4 are commonly inferred through the identification of glutathione adducts from the incubation medium. The utility of this strategy was confirmed with the mechanism-based inhibitor raloxifene and CYP3A4, whereby one of the reactive metabolites trapped with glutathione was also identified as the perpetrator of CYP3A4 inactivation mediated by raloxifene (Baer et al., 2007) . Unfortunately, in vitro studies designed to trap electrophilic intermediates from ritonavir bioactivation could not be detected by radiometric LC or LC/MS/MS from incubations with multiple trapping agents, which included glutathione (soft nucleophile) and cyanide (hard nucleophile). More so, co-incubations with these trapping agents had no effect on either the rate of inactivation by ritonavir or on the metabolite profile of ritonavir.
To characterize the potential for ritonavir electrophilic intermediate(s) to form adducts with CYP apoprotein, [ 3 H]-ritonavir, ritonavir and d 6 -ritonavir were employed. Historically, radiolabeled material traced the adducted protein through numerous steps including, dialysis, enzymatic digestion and LC/MS to facilitate the location of protein adducts (Racha et al., 1998; Lightning et al., 2000) (Lightning et al., 2000) . Given the inability to trap electrophilic intermediates of ritonavir with surrogate nucleophiles, it is suggestive that covalent binding of A series of studies were conducted to investigate the mechanism of ritonavir bioactivation and to identify the structure of the covalent adduct to CYP3A4 protein. The two thiazole rings (2'-isopropyl-thiazole and unsubstituted thiazole ring) were considered to be the likely sites of bioactivation based on a comparison of the inhibitory potencies of ritonavir and structural analogs (Kempf et al., 1997) . The results suggest that the potent inhibitory properties of ritonavir may require the presence of both thiazole rings in the molecule (Kumar et al., 1996) .
The literature on the CYP catalyzed bioactivation and metabolism thiazole rings is limited; however, the findings are highly relevant and provide insight into potential mechanisms for This article has not been copyedited and formatted. The final version may differ from this version. of oxidation of the thiazole ring to a reactive epoxide. The formation of this epoxide is highly dependent on the position of the substitutes on the thiazole ring. Subramanian and co-workers (Subramanian et al.) examined the metabolism of a library of variously substituted thiazole rings. In most cases, it was concluded that substitution at the 3'-position on the thiazole ring abolishes both epoxide formation and subsequent GSH adduct formation. Therefore, if epoxidation of ritonavir does occur, the most probable site of oxygen attack is on the unsubstituted thiazole ring. The results of the proteinase K digestion suggest that ritonavir is bioactivated at the opposite end of the molecule from the unsubsititued thiazole ring. Therefore, we propose the route of inactivation is most likely via a sulfoxide intermediate, followed by nucleophilic attack by the lysine residue (Scheme 1, pathway B).
In conclusion, ritonavir exhibited potent time-dependent inactivation of CYP3A, by which the mechanism of inactivation was through a covalent bond to Lys257 of the CYP3A4
This article has not been copyedited and formatted. The final version may differ from this version. apoprotein. Metabolism studies and inhibition profiles helped to eliminate heme adduction and MI complex by ritonavir and lead to the conclusion that CYP3A4 inactivation by ritonavir occurs via a covalent bond to the apoprotein. Intact whole protein mass spectroscopy was crucial to determine the mechanism of inactivation given the lack of a ritonavir adduct to any exdogenous trapping agents. However, the exact structure of the bioactivated ritonavir bound to the lysine residue remains unclear. Therefore, further investigation into the reactivity of thiazole rings and cytochrome CYP enzymes may provide further insights into the reactive intermediate structure This article has not been copyedited and formatted. The final version may differ from this version. 
